https://ift.tt/2RHmK9k The Drugs Controller General of India has approved the commercial launch of 'Feluda', the Tata CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) COVID-19 test, the Council of Scientific and Industrial Research (CSIR) said on Saturday.
DCGI approves commercial launch of low cost COVID-19 test 'Feluda'
Reviewed by MITESH
on
September 19, 2020
Rating: 5
No comments